HLA‐G 14‐bp polymorphism: a possible marker of systemic treatment response in psoriasis vulgaris? Preliminary results of a retrospective study. Issue 5 (9th June 2014)

• Record Type: Journal Article
• Authors: Borghi, Alessandro; Rizzo, Roberta; Corazza, Monica; Bertoldi, Alberto Maria; Bortolotti, Daria; Sturabotti, Giulia; Virgili, Annarosa; Di Luca, Dario
• Is Part Of: Dermatologic therapy. Volume 27:Issue 5(2014)
• Page Start: 284
• Page End: 289
• Publication Date: 2014-06-09
• Subjects: Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.12140
• Languages: English
• ISSNs: 1396-0296

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <p>Human leukocyte antigen‐G (HLA‐G) is a nonclassical HLA class I molecule that exerts an immunosuppressive function. A 14‐base pair (bp) sequence insertion/deletion (INS/DEL) polymorphism in the exon 8 at the 3′ untranslated region (UTR) modifies mRNA stability and protein production and has been shown to concur with efficacy of pharmacological treatments in immune‐mediated conditions. The aim of this study was to assess for the first time the correlation between HLA‐G 14‐bp INS/DEL polymorphism with the response to systemic therapy in psoriatic patients. We retrospectively analyzed the HLA‐G 14‐bp INS/DEL polymorphism of <italic>HLA</italic><italic>‐G</italic> gene in patients with moderate to severe plaque psoriasis: 21 treated with acitretin, 16 with cyclosporine, 11 with anti‐TNF‐α. Patients who reached PASI 75 at weeks 10–16 were considered responders. Among patients treated with acitretin, we observed a significantly increased frequency of the HLA‐G DEL allele and of the DEL/DEL genotype in responder patients when compared with nonresponders. An association between HLA‐G genotype and response to cyclosporine and biologics was not found. The significant association between HLA‐G 14‐bp DEL allele and 14‐bp DEL/DEL genotype and acitretin clinical outcome may suggest an advantage of this allele and propose this HLA‐G polymorphism as a potential marker of response to acitretin in psoriatic patients.</p> </abstract>